Exact Sciences presented data showing its Oncodetect minimal residual disease (MRD) assay identified post‑surgical triple‑negative breast cancer patients at significantly higher risk of distant recurrence when ctDNA was detected. Findings were shared from the NSABP B‑59 sub‑study at SABCS and showed that MRD negativity correlated with favorable three‑year distant recurrence‑free outcomes. Exact said it will submit the dataset to Medicare review (MolDx) to support reimbursement. The NSABP/German Breast Group collaboration and planned peer‑reviewed publication increase the evidence profile for circulating tumor DNA as a prognostic tool. For clinicians and payers: MRD assays may guide adjuvant therapy decisions, but prospective validation and coverage policies will determine clinical uptake.